Sign in Subscribe
Nanotechnology

Breakthrough in Nanoparticle Research Offers New Hope for Treatment of MRSA-Induced Infections

Strategic Insights

— 1 min read

Researchers from Central South University have developed a novel approach to treating methicillin-resistant Staphylococcus aureus (MRSA) infections using vancomycin-loaded and zoledronic acid-modified zeolitic imidazolate framework-8 (ZIF-8) nanoparticles. These nanoparticles, named VZZ-8 NPs, have been shown to effectively target bone metabolism and release zinc and vancomycin in a pH-dependent manner, disrupting bacterial membrane permeability and enhancing vancomycin's antimicrobial activity.

Key Takeaways:

  • The VZZ-8 NPs demonstrated a 93.84 ± 7.38 % eradication rate of MRSA and 95.36 ± 0.13 % inhibition of biofilm formation in vitro.
  • In a murine model of MRSA-induced periprosthetic joint infection, the VZZ-8 NPs displayed robust antibacterial efficacy while suppressing local TNF-a and IL-6 expression and preventing infection-mediated osteolysis.
  • The engineered VZZ-8 NPs provide an effective therapeutic approach for MRSA-induced PJI through their dual capability of targeted delivery and pH-responsive drug release.
  • Specific researchers involved in the study include Yixiao Pan, Shuailong Liang, Jiahao Wang, Zichao Jiang, Tianliang Ma, Sijie Chen, Mingyu Chen, Yinlin Wu, Yi Leng, Yihe Hu, and Long Wang from Hunan Engineering Research Center of Biomedical Metal and Ceramic Implants, Xiangya Hospital, Central South University.
  • The research was published in the Journal of Controlled Release, with the article titled "Bone-targeting ZIF-8 based nanoparticles loaded with vancomycin for the treatment of MRSA-induced periprosthetic joint infection" (Elsevier publishing).

Statistics:

  • The VZZ-8 NPs' efficacy in eradicating MRSA was demonstrated in vitro, with a success rate of 93.84 ± 7.38 %.
  • The nanoparticles also inhibited biofilm formation by 95.36 ± 0.13 % in vitro studies.
  • The VZZ-8 NPs' pH-dependent release of zinc and vancomycin was shown to disrupt bacterial membrane permeability and enhance antimicrobial activity.
  • The engineered nanoparticles demonstrated significant promise for treating MRSA-induced periprosthetic joint infections, with a comprehensive approach combining targeted delivery and pH-responsive drug release.

Sources:

  • NewsRx. Central South University Reports Findings in Nanoparticles (Bone-targeting ZIF-8 based nanoparticles loaded with vancomycin for the treatment of MRSA-induced periprosthetic joint infection). Nanotechnology Weekly. July 7, 2025; p 63.
  • Bone-targeting ZIF-8 based nanoparticles loaded with vancomycin for the treatment of MRSA-induced periprosthetic joint infection. Journal of Controlled Release, 2025:113965.
  • Journal of Controlled Release. (Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands. www.elsevier.com; www.journals.elsevier.com/journal-of-controlled-release/)

Read more